Finally the role of predictive biomarkers, such as PD-L1 expression, and prospective validation of minimal residual disease assessed by dynamic circulating tumour DNA (ctDNA) may help to personalise consolidation ICI strategy after CRT [77]. This evidence concerns the gene CD274 and neoplasm.